Journal
BIOCHEMICAL PHARMACOLOGY
Volume 85, Issue 3, Pages 396-403Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2012.11.004
Keywords
Interleukin-22; Interferon-alpha; Inflammation; STAT1
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG), Research, Development and Safety of Biopharmaceutical Drugs - Biologicals' [GRK1172]
Ask authors/readers for more resources
Besides their antiviral activity, type I Interferons (IFN) display context-specific immunomodulation. In contrast to long-known IFN alpha/beta, Interleukin (IL)-22 is an anti-bacterial, largely tissue protective cytokine that recently gained attention. Herein, cellular IFN alpha/IL-22 interactions are investigated. We report that pre-conditioning of epithelial cells with IFN alpha initiated dramatic changes in IL-22 signaling normally dominated by signal transducer and activator of transcription (STAT)-3. Specifically, by using human DLD1 colon epithelial/carcinoma cells we demonstrate that, upon IFN alpha, IL-22 converts into a cytokine robustly activating STAT1 and its downstream pro-inflammatory targets CXCL9, CXCL10, and inducible nitric oxide synthase (iNOS). Accordingly, only after IFN alpha pre-incubation was IL-22-induced STAT1 binding to the CXCL10 promoter detectable. Using the viral mimic polyinosinic polycytidylic acid and the IFN alpha/beta antagonist B18R we furthermore demonstrate the capability of endogenous IFN to promote IL-22-induced STAT1 activation and expression of CXCL10. IL-22-induced STAT1 activation subsequent to IFN alpha priming became likewise apparent in human Caco2 colon epithelial/carcinoma cells, HepG2 hepatoma cells, and primary keratinocytes. Current observations may relate to characteristics of IFN alpha/beta in clinical therapy and expose margins of tissue protection by IL-22 application. (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available